Good news for some .................new drug
NERLYNX^® (neratinib) now approved by the Therapeutic Goods Administration for Australian women^2
· Leading Australian breast cancer oncologist says this is a 'huge step forward' for Australian women
· Five-year data shows NERLYNX reduces the risk of invasive disease recurrence or death by 42% in women with early-stage, HER2+/HR+ breast cancer^3
· NERLYNX now available to eligible women at no cost in Australia via the NERLYNX Access Program
The drug, NERLYNX (neratinib) is an oral medication taken for 12 months by women with early stage HER2-positive (HER2+) breast cancer. It is now TGA approved with the following indication:
*"NERLYNX is indicated for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab based therapy."^2*
The greatest benefit is seen in women who are hormone-receptor positive (HR+) and who initiate NERLYNX therapy within 12 months of completing trastuzumab based therapy. Their five-year risk of recurrence or death is reduced by 42% after completing 12 months of NERLYNX therapy.^3
· Leading Australian breast cancer oncologist says this is a 'huge step forward' for Australian women
· Five-year data shows NERLYNX reduces the risk of invasive disease recurrence or death by 42% in women with early-stage, HER2+/HR+ breast cancer^3
· NERLYNX now available to eligible women at no cost in Australia via the NERLYNX Access Program
The drug, NERLYNX (neratinib) is an oral medication taken for 12 months by women with early stage HER2-positive (HER2+) breast cancer. It is now TGA approved with the following indication:
*"NERLYNX is indicated for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab based therapy."^2*
The greatest benefit is seen in women who are hormone-receptor positive (HR+) and who initiate NERLYNX therapy within 12 months of completing trastuzumab based therapy. Their five-year risk of recurrence or death is reduced by 42% after completing 12 months of NERLYNX therapy.^3
